Caricamento...
Contraindications to intravenous rtPA for acute stroke: A critical reappraisal
Only 1%–5% of patients with acute ischemic stroke presenting within 3 hours of symptoms receive IV recombinant tissue plasminogen activator (rtPA)—the only effective treatment available. The administration of rtPA is limited by extensive exclusion criteria, many of which are not based on evidence, b...
Salvato in:
| Pubblicato in: | Neurol Clin Pract |
|---|---|
| Autori principali: | , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
American Academy of Neurology
2013
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5798502/ https://ncbi.nlm.nih.gov/pubmed/29473642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/CPJ.0b013e318296f0a9 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|